Trial Profile
An Exploratory Study of Rebamipide to Evaluate Efficacy and Safety in the Treatment of Dry Mouth in Patients With Sjögren's Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Mar 2022
Price :
$35
*
At a glance
- Drugs Rebamipide (Primary)
- Indications Sjogren's syndrome; Xerostomia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 19 Apr 2014 New trial record